Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Search results from the "OB_Rx" table for query on "200533."

Active Ingredient:	TAPENTADOL HYDROCHLORIDE
Dosage Form;Route:	TABLET, EXTENDED RELEASE;ORAL
Proprietary Name:	NUCYNTA ER
Applicant:	JANSSEN PHARMS
Strength:	EQ 50MG BASE
Application Number:	N200533
Product Number:	001
Approval Date:	Aug 25, 2011
Reference Listed Drug	No
RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	View

Active Ingredient:	TAPENTADOL HYDROCHLORIDE
Dosage Form;Route:	TABLET, EXTENDED RELEASE;ORAL
Proprietary Name:	NUCYNTA ER
Applicant:	JANSSEN PHARMS
Strength:	EQ 100MG BASE
Application Number:	N200533
Product Number:	002
Approval Date:	Aug 25, 2011
Reference Listed Drug	No
RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	View

Active Ingredient:	TAPENTADOL HYDROCHLORIDE
Dosage Form;Route:	TABLET, EXTENDED RELEASE;ORAL
Proprietary Name:	NUCYNTA ER
Applicant:	JANSSEN PHARMS
Strength:	EQ 150MG BASE
Application Number:	N200533
Product Number:	003
Approval Date:	Aug 25, 2011
Reference Listed Drug	No
RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	View

Active Ingredient:	TAPENTADOL HYDROCHLORIDE
Dosage Form;Route:	TABLET, EXTENDED RELEASE;ORAL
Proprietary Name:	NUCYNTA ER
Applicant:	JANSSEN PHARMS
Strength:	EQ 200MG BASE
Application Number:	N200533
Product Number:	004
Approval Date:	Aug 25, 2011
Reference Listed Drug	No

RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	View
Active Ingredient:	TAPENTADOL HYDROCHLORIDE
Dosage Form;Route:	TABLET, EXTENDED RELEASE;ORAL
Proprietary Name:	NUCYNTA ER
Applicant:	JANSSEN PHARMS
Strength:	EQ 250MG BASE
Application Number:	N200533
Product Number:	005
Approval Date:	Aug 25, 2011
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	
Patent and Exclusivity Info for this product:	View

Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 17, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 001 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	001	6071970	Jun 6, 2017			U - 1178	
N200533	001	6071970	Jun 6, 2017			U - 1276	
N200533	001	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	001	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	001	8075872	Nov 20, 2023		Y		
N200533	001	8114383	Oct 10, 2024		Y		Y
N200533	001	8309060	Nov 20, 2023		Y	U - 1178	
N200533	001	8309060	Nov 20, 2023		Y	U - 1276	
N200533	001	8420056	Nov 20, 2023		Y		
N200533	001	8536130	Sep 22, 2028			U - 1276	
N200533	001	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	001	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	001	I - 656	Aug 28, 2015
N200533	001	NCE	Nov 20, 2013
N200533	001	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes

Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 12, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 002 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	002	6071970	Jun 6, 2017			U - 1178	
N200533	002	6071970	Jun 6, 2017			U - 1276	
N200533	002	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	002	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	002	8075872	Nov 20, 2023		Y		
N200533	002	8114383	Oct 10, 2024		Y		Y
N200533	002	8309060	Nov 20, 2023		Y	U - 1178	
N200533	002	8309060	Nov 20, 2023		Y	U - 1276	
N200533	002	8420056	Nov 20, 2023		Y		
N200533	002	8536130	Sep 22, 2028			U - 1276	
N200533	002	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	002	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	002	I - 656	Aug 28, 2015
N200533	002	NCE	Nov 20, 2013
N200533	002	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes
Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 003 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	003	6071970	Jun 6, 2017			U - 1178	
N200533	003	6071970	Jun 6, 2017			U - 1276	
N200533	003	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	003	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	003	8075872	Nov 20, 2023		Y		
N200533	003	8114383	Oct 10, 2024		Y		Y
N200533	003	8309060	Nov 20, 2023		Y	U - 1178	
N200533	003	8309060	Nov 20, 2023		Y	U - 1276	
N200533	003	8420056	Nov 20, 2023		Y		
N200533	003	8536130	Sep 22, 2028			U - 1276	
N200533	003	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	003	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	003	I - 656	Aug 28, 2015
N200533	003	NCE	Nov 20, 2013
N200533	003	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes
Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 004 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	004	6071970	Jun 6, 2017			U - 1178	
N200533	004	6071970	Jun 6, 2017			U - 1276	
N200533	004	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	004	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	004	8075872	Nov 20, 2023		Y		
N200533	004	8114383	Oct 10, 2024		Y		Y
N200533	004	8309060	Nov 20, 2023		Y	U - 1178	
N200533	004	8309060	Nov 20, 2023		Y	U - 1276	
N200533	004	8420056	Nov 20, 2023		Y		
N200533	004	8536130	Sep 22, 2028			U - 1276	
N200533	004	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	004	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	004	I - 656	Aug 28, 2015
N200533	004	NCE	Nov 20, 2013
N200533	004	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes
Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Patent and Exclusivity Search Results from query on Appl No 200533 Product 005 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N200533	005	6071970	Jun 6, 2017			U - 1178	
N200533	005	6071970	Jun 6, 2017			U - 1276	
N200533	005	7994364	Jun 27, 2025	Y	Y	U - 1178	
N200533	005	7994364	Jun 27, 2025	Y	Y	U - 1276	
N200533	005	8075872	Nov 20, 2023		Y		
N200533	005	8114383	Oct 10, 2024		Y		Y
N200533	005	8309060	Nov 20, 2023		Y	U - 1178	
N200533	005	8309060	Nov 20, 2023		Y	U - 1276	
N200533	005	8420056	Nov 20, 2023		Y		
N200533	005	8536130	Sep 22, 2028			U - 1276	
N200533	005	RE39593	Aug 5, 2022	Y	Y	U - 1178	
N200533	005	RE39593	Aug 5, 2022	Y	Y	U - 1276	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N200533	005	I - 656	Aug 28, 2015
N200533	005	NCE	Nov 20, 2013
N200533	005	NDF	Aug 25, 2014

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes
Return to Electronic Orange Book Home Page[6]

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through November 2014
Patent and Generic Drug Product Data Last Updated December 18, 2014

Links on this page:

1. http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain
2. http://www.addthis.com/bookmark.php
3. http://www.fda.gov/default.htm
4. http://www.fda.gov/Drugs/InformationOnDrugs/default.htm
5. ../default.cfm
6. ../default.cfm

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

Pharmacist often relies on orange book codes for therapeutic substitution when permitted by prescriber. In this mini review, we made sincere efforts to explain Orange book, therapeutic equivalent codes and how to interpret each code. Keywords: orange book, therapeutic equivalence, AB ratings. Volume 1 Issue 3 - 2015. Vijay M Kale.Â The official name of FDAâ€™s orange book is Approved Drug Products with Therapeutic Equivalence Evaluations. Originally this book was published in October 1980 with orange cover and thus the name â€œorange bookâ€. The orange book is published annually and the 2015 edition is 35th edition of orange book.1 It is freely available for download and it has search options available on website. Product categories. Drug Patent Reports. FDA Orange Book. Finding and evaluating generic and branded drug market entry opportunities. Get the book: Make Better Decisions. Popular Posts. Drug Patent Life: How Long Do Drug Patents Last? Top 6 issues facing the biotechnology industry. 244 Drug Patents With Claims Containing â€œconsisting essentially ofâ€ may be Unenforceable.Â Pharmaceutical News. DrugPatentWatch - Make Better DecisionsBusiness Intelligence on Biologic and Small Molecule Drugs. Startup Blog by Compete Themes. Close this module. Get the DrugPatentWatch Daily Briefing. â€“ Patent Expirations and Generic Entry â€“ 505(b)(2) & Biosimilars â€“ Insightful Articles & Case Studies â€“ Patent Litigation & Challenges. The Orange Book identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The publication does not include drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal Tablets and Librax Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]).Â In addition, the Orange Book contains therapeutic equivalence evaluations (2 character rating codes) for approved multisource prescription drug products (generic drugs).